CJC-1295 / IpamorelinvsRetatrutide
CJC-1295 / Ipamorelin vs Retatrutide — independent comparison of uses, administration, pricing across providers, and key differences. Last reviewed April 21, 2026.
Quick Verdict
Based on clinical evidence and real patient data
A combination of a growth hormone-releasing hormone analog (CJC-1295) and a growth hormone secretagogue (Ipamorelin). Together they stimulate natural growth hormone production without significantly raising cortisol or prolactin.
A next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show weight loss exceeding tirzepatide, positioning it as the most potent anti-obesity peptide in development.
Best choice depends on your insurance, budget, and treatment history.Take the quiz to get a personalized recommendation.
CJC-1295 / Ipamorelin vs Retatrutide: At a Glance
Full comparison across all key factors.
| Factor | CJC-1295 / IpamorelinALLY PICK | Retatrutide |
|---|---|---|
| Category | growth-hormone | weight-loss |
| Also Known As | CJC-1295, Ipamorelin, CJC/Ipa | LY3437943 |
| Administration | Subcutaneous injection | Subcutaneous injection (weekly) |
| Prescription | Required | Required |
| Providers | 9 providers✓ Better | 3 providers |
| Common Uses |
|
|
Data sourced from FDA prescribing information and peer-reviewed clinical trials. Prices reflect telehealth platform costs as of April 21, 2026. See our methodology.
Pricing by Provider
3 providers offer both CJC-1295 / Ipamorelin and Retatrutide.
| Provider | CJC-1295 / Ipamorelin | Retatrutide | Consultation | Lab Testing |
|---|---|---|---|---|
 | $180/monthly | $450/monthly | Video Telehealth | Yes |
 | $195/monthly | $480/monthly | Video Telehealth | Yes |
 | $250/monthly | $550/monthly | Video Telehealth | Yes |
| Price unavailable | Not offered | Hybrid | No | |
 | $45/one-time | Not offered | Async Telehealth | No |
 | $160/monthly | Not offered | Video Telehealth | No |
 | $199/monthly | Not offered | Async Telehealth | Yes |
 | $199/monthly | Not offered | Video Telehealth | Yes |
| Price unavailable | Not offered | Async Telehealth | No |
Key Differences
CJC-1295 / Ipamorelin
More ProvidersA combination of a growth hormone-releasing hormone analog (CJC-1295) and a growth hormone secretagogue (Ipamorelin). Together they stimulate natural growth hormone production without significantly raising cortisol or prolactin.
Retatrutide
A next-generation triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show weight loss exceeding tirzepatide, positioning it as the most potent anti-obesity peptide in development.
Which Is Right for You?
Choose CJC-1295 / Ipamorelinif…
- You want a growth-hormone medication
- You prefer subcutaneous injection administration
- You want more provider options (9 available)
- Your primary goal is increased lean muscle mass
- Your primary goal is fat loss
Choose Retatrutideif…
- You want a weight-loss medication
- You prefer subcutaneous injection (weekly) administration
- 3 providers available on our platform
- Your primary goal is weight loss
- Your primary goal is metabolic health
Frequently Asked Questions
What is the difference between CJC-1295 / Ipamorelin and Retatrutide?
Which is cheaper, CJC-1295 / Ipamorelin or Retatrutide?
Can I switch from CJC-1295 / Ipamorelin to Retatrutide?
Medical Disclaimer
This comparison is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication. Individual results may vary. The information presented reflects publicly available data and may not account for your specific health situation.
Related Guides
Retatrutide: The Triple-Agonist GLP-1 That Could Change Everything
Complete guide to retatrutide — Eli Lilly's triple-agonist (GLP-1/GIP/glucagon) with 28.7% weight loss in trials. Clinical data, how it compares, and when it might be available.
Read guide →Retatrutide Cost: What Will Eli Lilly's Triple-Agonist Cost When It Launches?
No official pricing exists for retatrutide — it hasn't been FDA-approved. Based on Lilly's existing portfolio, expect a list price of $1,000-1,500/mo with LillyDirect pricing potentially reducing that to $299-449/mo. Here's what we know, what we can project, and how to prepare.
Read guide →Retatrutide Dosing Guide: Titration Schedule, Dose Steps & What to Expect
Complete retatrutide dosing guide based on TRIUMPH Phase 3 clinical trial protocols. Titration schedule from 1mg to 12mg, dose adjustments, side effects at each step, and comparison to semaglutide and tirzepatide dosing.
Read guide →